X0407 4 2022-09-30-05:00 false 0001443863 BioCorRx Inc. BICX 0001198613 GALLIGAN JOSEPH J 2390 EAST ORANGEWOOD AVENUE SUITE 500 ANAHEIM CA 92806 true false true false false Common Stock, par value $0.001 2022-09-30-05:00 4 A false 2450 0 A 40931 D Common Stock, par value $0.001 2022-12-30-05:00 4 A false 5319 0 A 46250 D Common Stock, par value $0.001 2023-03-29-05:00 4 P false 171296 1.75 A 217546 I By Trust Common Stock, par value $0.001 2023-03-31-05:00 4 A false 2824 0 A 220370 D Common Stock, par value $0.001 2023-06-30-05:00 4 A false 2891 0 A 223261 D These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $2.04. These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.94. These shares were issued to The J and R Galligan Revocable Trust, managed by Mr. Joseph M. Galligan (the "Galligan Trust") pursuant to a subscription agreement by and between BioCorRx Inc. and the Galligan Trust dated March 29 2023, and paid for on March 30, 2023. The Reporting Person may be deemed to have investment power over the Galligan Trust. These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.77. These shares were issued to Mr. Galligan pursuant to a Director Agreement, dated February 16, 2021, by and between BioCorRx Inc. and Mr. Galligan. As compensation for his services, Mr. Galligan shall be issued, upon the last day of each fiscal quarter, provided Mr. Galligan is a member of the Board as of such date, the number of shares of the Company's common stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $1.73. /s/ Joseph J. Galligan 2023-07-06-05:00